BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 27956700)

  • 1. mTORC1 and -2 Coordinate Transcriptional and Translational Reprogramming in Resistance to DNA Damage and Replicative Stress in Breast Cancer Cells.
    Silvera D; Ernlund A; Arju R; Connolly E; Volta V; Wang J; Schneider RJ
    Mol Cell Biol; 2017 Mar; 37(5):. PubMed ID: 27956700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA damage-induced S and G2/M cell cycle arrest requires mTORC2-dependent regulation of Chk1.
    Selvarajah J; Elia A; Carroll VA; Moumen A
    Oncotarget; 2015 Jan; 6(1):427-40. PubMed ID: 25460505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
    Guichard SM; Curwen J; Bihani T; D'Cruz CM; Yates JW; Grondine M; Howard Z; Davies BR; Bigley G; Klinowska T; Pike KG; Pass M; Chresta CM; Polanska UM; McEwen R; Delpuech O; Green S; Cosulich SC
    Mol Cancer Ther; 2015 Nov; 14(11):2508-18. PubMed ID: 26358751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
    Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB
    Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells.
    Zhou X; Liu W; Hu X; Dorrance A; Garzon R; Houghton PJ; Shen C
    Sci Rep; 2017 May; 7(1):1535. PubMed ID: 28484242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.
    Musa F; Alard A; David-West G; Curtin JP; Blank SV; Schneider RJ
    Mol Cancer Ther; 2016 Jul; 15(7):1557-67. PubMed ID: 27196780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restriction of dietary protein decreases mTORC1 in tumors and somatic tissues of a tumor-bearing mouse xenograft model.
    Lamming DW; Cummings NE; Rastelli AL; Gao F; Cava E; Bertozzi B; Spelta F; Pili R; Fontana L
    Oncotarget; 2015 Oct; 6(31):31233-40. PubMed ID: 26378060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
    Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A
    Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition.
    Yoon SO; Shin S; Karreth FA; Buel GR; Jedrychowski MP; Plas DR; Dedhar S; Gygi SP; Roux PP; Dephoure N; Blenis J
    Mol Cell; 2017 Aug; 67(3):512-527.e4. PubMed ID: 28757207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
    Qian J; Chen Y; Meng T; Ma L; Meng L; Wang X; Yu T; Zask A; Shen J; Yu K
    Oncotarget; 2016 Oct; 7(41):67071-67086. PubMed ID: 27563814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
    Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
    PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.
    Mortensen DS; Fultz KE; Xu S; Xu W; Packard G; Khambatta G; Gamez JC; Leisten J; Zhao J; Apuy J; Ghoreishi K; Hickman M; Narla RK; Bissonette R; Richardson S; Peng SX; Perrin-Ninkovic S; Tran T; Shi T; Yang WQ; Tong Z; Cathers BE; Moghaddam MF; Canan SS; Worland P; Sankar S; Raymon HK
    Mol Cancer Ther; 2015 Jun; 14(6):1295-305. PubMed ID: 25855786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells.
    Sini P; James D; Chresta C; Guichard S
    Autophagy; 2010 May; 6(4):553-4. PubMed ID: 20364113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment.
    Cao J; Huang W
    PLoS One; 2016; 11(2):e0149388. PubMed ID: 26872016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
    Zhang X; Wang X; Xu T; Zhong S; Shen Z
    Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo.
    Zhang Y; Xu S; Lin J; Yao G; Han Z; Liang B; Zou Z; Chen Z; Song Q; Dai Y; Gao T; Liu A; Bai X
    Breast Cancer Res Treat; 2012 Nov; 136(2):379-88. PubMed ID: 23053656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza virus differentially activates mTORC1 and mTORC2 signaling to maximize late stage replication.
    Kuss-Duerkop SK; Wang J; Mena I; White K; Metreveli G; Sakthivel R; Mata MA; Muñoz-Moreno R; Chen X; Krammer F; Diamond MS; Chen ZJ; García-Sastre A; Fontoura BMA
    PLoS Pathog; 2017 Sep; 13(9):e1006635. PubMed ID: 28953980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK.
    Zhou H; Shang C; Wang M; Shen T; Kong L; Yu C; Ye Z; Luo Y; Liu L; Li Y; Huang S
    Biochem Pharmacol; 2016 Sep; 116():39-50. PubMed ID: 27396756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.